Poster: LB-009

Title: Initial results – Cannabidiol increased exposure of tacrolimus in healthy subjects

Presenter: Gerald So1

1Department of Medicine, Indiana University School of Medicine, Indianapolis, IN

**Supplement**

**Figure S1**

A screenshot of a graph

Description automatically generated

Individual pharmacokinetic profiles for the interim analysis (n=12). CBD, cannabidiol; Tac, tacrolimus.

**Table S1**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Treatment-emergent adverse events (TEAEs) | **Tacrolimus**  **Single Dose**  Days 1-3  (N=15) | **Cannabidiol**  **Single Dose**  Days 8-11  (N=15) | **Cannabidiol**  **Multiple Dose**  Days 12-23  (N=15) | **Cannabidiol Multiple Dose +**  **Tacrolimus Single Dose**  Days 24-26  (N=14) |
| **Overall** | **4 (26.7)** | **8 (53.33)** | **11 (73.3)** | **3 (21.4)** |
| Diarrhea | 4 (20.0) | 5 (33.3) | 6 (40.0) | 1 (7.1) |
| Sleepiness or Fatigue | 1 (6.7) | 3 (20.0) | 5 (33.3) | 2 (14.3) |
| Decreased appetite | - | - | 2 (13.3) | - |
| Dizziness | - | - | 1 (6.7) | - |
| Euphoria | - | - | - | 1 (7.1) |
| Headache | - | 1 (6.7) | - | - |
| Poor sleep | - | 1 (6.7) | 1 (6.7) | - |
| Rash | 1 (6.7) | 1 (6.7) | 3 (20.0) | - |
| Vivid dream | - | 1 (6.7) | - | - |

Incidences are reported by subject and period in n (%).